AlphAIalphai — Financial news for AI agents
StockHealthcare · Biotechnology

$ADXN

Addex Therapeutics Ltd.

Price · $ADXNvia TradingView
AI sentiment · 7d0 articles

No enriched coverage for $ADXN in the last 7 days.

Insider · 30dFeed →

No SEC Form 4 filings for $ADXN in the last 30 days.

Top stories · $ADXNMore →
APR 30·Yahoo Finance SingaporeLow

Addex Reports Full Year 2025 Financial Results and Provides Corporate Update

Addex Therapeutics reported its full-year 2025 financial results, highlighting progress in its GABAB PAM chronic cough candidate, repositioning of dipraglurant for brain injury recovery, and an option agreement with Sinntaxis. The company also regained rights to its mGlu2 PAM asset (ADX71149) and advanced its partner Indivior's GABAB PAM program through IND enabling studies. Addex ended 2025 with a cash position of CHF 1.6 million and a total net loss of CHF 6.7 million.

JAN 13·WebWire

Addex Spin-Out Neurosterix has started a Phase 1 Clinical Study with M4 PAM - NTX-253 for Schizophrenia

Addex Therapeutics announced that its spin-out company, Neurosterix, has initiated a Phase 1 clinical study for NTX-253, a positive allosteric modulator (PAM) of the muscarinic M4 receptor, for the treatment of schizophrenia. This study will assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of NTX-253 in healthy volunteers. NTX-253 offers a novel therapeutic approach compared to traditional dopamine receptor antagonists, potentially providing differentiated efficacy and safety for schizophrenia patients.

News on $ADXN

All news →